Europe’s largest annual dermatology meeting, the
The EADV 2025 Congress, held in Paris, France from September 17-20, 2025, was no exception. The meeting delivered session after session of impactful data, including 6 late-breaking sessions with more than 2 dozen studies total spanning an array of dermatologic conditions.
To celebrate the meeting, the HCPLive Dermatology editorial staff has compiled a list of 13 late-breaking trials for clinicians to know from EADV Congress 2025—divided by disease state.
EADV Congress: Psoriasis Late-Breakers to Know
ICONIC-ADVANCE: Icotrokinra Beats Deucravacitinib for Plaque Psoriasis
Icotrokinra, Johnson & Johnson’s first-in-class oral IL-23 inhibitor, outperformed deucravacitinib in head-to-head phase 3 trials, marking a potential shift in treatment options for moderate to severe plaque psoriasis.
In the ICONIC-ADVANCE program, the agent met co-primary endpoints at Week 16 and achieved superior rates of complete skin clearance at Weeks 16 and 24. Long-term findings from ICONIC-LEAD showed durable efficacy, with 84% of responders maintaining PASI 90 at Week 52 compared to 21% on placebo. Safety outcomes were favorable, with adverse event rates similar to placebo, numerically lower than deucravacitinib, and no new safety signals identified.
Bimekizumab Effective in Bio-Naïve, Bio-Experienced Patients with Psoriasis
Bimekizumab (Bimzelx), a selective IL-17A/F inhibitor, demonstrated strong efficacy in both biologic-naïve and biologic-experienced adults with psoriasis, with faster onset in bio-naïve patients.
In a 341-patient cohort, PASI75, PASI90, and PASI100 response rates reached 97.3%, 93.9%, and 74.8%, respectively, by week 24. Predictors of reduced likelihood of early super response included family history, palmoplantar involvement, psoriatic arthritis, and prior biologic exposure. The most common adverse event was candidiasis (13.7%), occurring more frequently in biologic-experienced patients, females, and those with multiple prior biologic failures.
POSITIVE: Tildrakizumab Has Significant Impact on QoL in Psoriatic Disease
The POSITIVE study, a 24-month, multinational, real-world trial, demonstrated that tildrakizumab (Ilumya) improves both clinical outcomes and psychological well-being in patients with psoriatic disease.
By week 16, WHO-5 scores reached European population norms and continued to rise above baseline through two years, while PASI scores decreased rapidly and remained low, with nearly 80% of patients maintaining PASI ≤2 at two years. Quality-of-life and family burden measures also showed sustained benefit, though nearly one-third of patients experienced “psycholag,” with skin improvement preceding psychological recovery.
EADV Congress: Atopic Dermatitis Late-Breakers to Know
Temtokibart, an investigational IL-22RA1–targeting monoclonal antibody from LEO Pharma, improved disease severity and biomarker profiles in adults with moderate-to-severe atopic dermatitis in phase 2b data. In a 262-patient trial, temtokibart produced significantly greater EASI improvements at week 16 versus placebo, with responses observed as early as week 1 in some dosing arms and maintained to week 32 despite treatment cessation after week 14.
A biomarker analysis showed 97% improvement in immune gene expression and restoration of epidermal barrier–related genes by Week 16, with reductions in Th2 and Th17/22 markers correlating with clinical benefit. Safety data were consistent with prior findings, with no unexpected signals.
ECZTEND: Tralokinumab Use Leads to Stable Long-Term Effects in Atopic Dermatitis
New long-term data from the ECZTRA 3 and ECZTEND trials show that patients with moderate-to-severe atopic dermatitis who respond to tralokinumab (Adbry) at 16 weeks can maintain durable disease control for up to 3 years.
Across responder groups, 60% or more of patients remained on treatment at Week 120, with stable improvements in EASI scores and quality-of-life measures. Lower absolute EASI scores at Week 16 strongly predicted long-term benefit, and nearly half of patients who achieved both EASI-90 and DLQI 0/1 at 16 weeks sustained that composite response throughout follow-up.
EADV 2025 Congress: Alopecia Late-Breakers to Know
ALLEGRO 3-Year Data Demonstrate Effectiveness in Alopecia Areata for Adults, Adolescents
Three-year follow-up data from the ALLEGRO program presented at EADV 2025 confirmed the long-term durability of ritlecitinib (Litfulo) in alopecia areata.
Nearly 90% of patients who achieved a SALT score ≤20 at 12 months maintained this response through 36–38 months, with almost 30% achieving complete scalp hair regrowth. Eyebrow and eyelash responses were also sustained in about half of patients. No new safety concerns were identified, and the long-term safety profile was consistent with prior findings.
JAK3/TEC Inhibition Through Ritlecitinib Effective, Safe for Cicatricial Alopecias
Ritlecitinib demonstrated rapid clinical and molecular improvements across multiple forms of cicatricial alopecia, with a favorable safety profile, according to phase 2 data.
In 50 patients with lichen planopilaris, frontal fibrosing alopecia, or central centrifugal cicatricial alopecia, ritlecitinib treatment led to significant improvements in disease activity scores by week 24, with further gains through week 48. Molecular analyses showed broad downregulation of inflammatory pathways, particularly in central centrifugal cicatricial alopecia, with early changes observed as soon as Week 8. The regimen was well tolerated, with mostly mild to moderate adverse events and no new safety concerns.
EADV Congress: Hidradenitis Suppurativa Late-Breakers to Know
Povorcitinib Improves Moderate to Severe Hidradenitis Suppurativa at Week 24
Bimekizumab has shown long-term disease control is possible for patients with this difficult-to-treat condition.
In the BE HEARD I and II phase 3 trials and their open-label extension, efficacy was sustained through 3 years, with HiSCR75 achieved in 81.2% of patients and HiSCR100 in 50.1%. Improvements in IHS4 responses and quality of life were also maintained, underscoring the drug’s potential to prevent structural damage.
Izokibep Effective in 16 Weeks Among Patients with Moderate to Severe Hidradenitis Suppurativa
Izokibep, a novel IL-17A inhibitor, shows promise in new data from a phase 2b/3 randomized controlled trial of adults with moderate to severe hidradenitis suppurativa.
Patients receiving izokibep achieved early and clinically meaningful improvements in HiSCR50/75/90/100, pain reduction, abscess and nodule counts, and quality of life at Week 16, with benefits sustained through Week 76. More than one-third of participants reached HiSCR75 and over 20% achieved HiSCR100, indicating complete lesion clearance in some patients.
EADV Congress: Chronic Hand Eczema Late-Breakers to Know
Pooled Phase 2/3 Data on Delgocitinib Illustrate Consistent Safety Profile in CHE
Delgocitinib cream (Anzupgo), a topical pan-JAK inhibitor, was effective and well tolerated in adolescents with moderate to severe chronic hand eczema (CHE) in the phase 3 DELTA TEEN trial.
At week 16, 63.5% of patients treated with delgocitinib achieved Investigator’s Global Assessment–CHE Treatment Success compared with 29.2% on vehicle. Treatment was also associated with higher rates of HECSI-90 response and significant reductions in itch, pain, and symptom scores.
Pooled Phase 2/3 Data on Delgocitinib Illustrate Consistent Safety Profile in CHE
A pooled safety analysis of nearly 5 phase 2 and 3 trials confirmed the consistent safety profile of delgocitinib cream in adults with moderate to severe CHE.
Adverse event rates with delgocitinib were similar to vehicle and lower than oral alitretinoin, with event frequency declining over time during as-needed treatment. Findings reinforce the agent’s favorable risk-benefit profile, which supported FDA approval in July 2025 as the first treatment for CHE. The data add to phase 3 results from the DELTA TEEN trial, which demonstrated efficacy and safety in adolescents.
More EADV Congress Late-Breakers to Know
Pooled Phase 3 Data on Ruxolitinib Highlights Benefit in Prurigo Nodularis
Ruxolitinib cream 1.5% (Opzelura), a topical JAK1/JAK2 inhibitor, demonstrated significant efficacy and favorable safety in adults with prurigo nodularis in pooled phase 3 TRuE-PN1 and TRuE-PN2 trial data.
At week 12, 42.3% of patients achieved ≥4-point reduction in Worst Itch Numerical Rating Scale versus 28.1% with vehicle, with improvements in Investigator’s Global Assessment–Chronic Prurigo scores and overall treatment success. Responses were maintained through week 24, including among those who switched from vehicle to active treatment.
Remibrutinib Lowers Specific IgG Autoantibody Levels in Individuals with CSU
Remibrutinib, an oral Bruton tyrosine kinase inhibitor, significantly reduced elevated IgG autoantibody levels in patients with chronic spontaneous urticaria (CSU), particularly those with a positive Chronic Urticaria Index (CUI+), according to new REMIX trial data.
Among CUI+ patients, notable decreases in FcεRI- and thyroglobulin-specific IgG autoantibodies were observed by Week 24 compared with placebo. Patients switched from placebo to remibrutinib at Week 24 showed similar reductions by week 52. Reductions in autoantibody levels were accompanied by decreased non-switched memory B cells and soluble CD23, suggesting a direct effect on B-cell activation.